
ASLN
Healthcare · Biotechnology · $1.7M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2024
EPS trend, 90 days to now · -566.7% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 12, 2024 | Before the open | -0.65 | -0.78 | -20.0% |
| Jan 10, 2024 | Before the open | -0.65 | -0.78 | -20.0% |
| Oct 27, 2023 | Before the open | -0.78 | -0.56 | +28.2% |
| Aug 11, 2023 | Before the open | -0.80 | -0.11 | +86.3% |
| Apr 28, 2023 | Before the open | -4.05 | -1.29 | +68.1% |
| Mar 24, 2023 | Before the open | -0.89 | -1.04 | -16.9% |
| Oct 28, 2022 | Before the open | -0.95 | -0.80 | +15.8% |
| Aug 12, 2022 | Before the open | -0.60 | -0.95 | -58.3% |
| Apr 27, 2022 | Before the open | -0.52 | -0.95 | -82.7% |
| Mar 25, 2022 | Before the open | -0.72 | -0.80 | -11.1% |
| Oct 26, 2021 | Before the open | -0.65 | -0.60 | +7.7% |
| Aug 6, 2021 | Before the open | -0.55 | -0.35 | +36.4% |
| Apr 22, 2021 | Before the open | -0.50 |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and…
| -0.75 |
| -50.0% |
| Nov 9, 2020 | Before the open | -0.47 | -0.50 | -6.4% |
| Jul 21, 2020 | After the close | -0.40 | -0.52 | -30.0% |
| May 11, 2020 | After the close | -0.40 | -0.50 | -25.0% |
| Mar 18, 2020 | Before the open | -0.85 | -4.50 | -429.4% |
| Oct 31, 2019 | Before the open | -1.15 | -0.75 | +34.8% |
| Aug 13, 2019 | Before the open | -1.00 | -1.24 | -24.0% |
| Apr 29, 2019 | Before the open | -0.90 | -0.67 | +25.6% |
| Mar 22, 2019 | Before the open | -2.23 | -1.75 | +21.5% |
| Nov 8, 2018 | Before the open | -1.70 | -1.75 | -2.9% |
| Aug 6, 2018 | Before the open | -1.57 | -1.75 | -11.5% |
| May 14, 2018 | After the close | -0.47 | -0.33 | +29.8% |
| Jan 18, 2018 | Time not confirmed | — | -0.31 | — |